Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


You Just Have To Wait: FDA Can't Hurry PDUFA VI Guidances

Executive Summary

In response to stakeholder concern about multi-year schedule for patient-input guidance development, FDA says it only has a few experts and has to balance their time.


Related Content

Woodcock Wants Rapid Regulatory Policy Development
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
PDUFA VI: Industry Ready For 'Hard Sell' To Keep Agreement Intact
Woodcock, Califf Give Thumbs Up To Certain 21st Century Cures Provisions
Quality-Of-Life, Emotional Well-Being Becoming Highly Utilized PROs In Diabetes Trials
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
Patient-Focused Drug Development At 10: Where Does It Go From Here?
FDA Needs Formal Mechanism To Integrate Patient Input, Groups Say





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts